Amgen UK’s Chris Fox: Up for the Challenge
Christine (Chris) Fox, VP general manager UK and Ireland at Amgen discusses the rationale behind taking on the management of a UK affiliate in challenging times and the specificities of…
Address: Bristol-Myers Squibb Pharmaceuticals Limited (Uxbridge), MS House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH, United Kingdom
Tel: +44 (0)1895 523000
Since 1858, medicines made by Bristol-Myers Squibb have helped millions of patients around the world fight serious diseases such as cancer, heart disease, diabetes, HIV/AIDS, chronic hepatitis B, rheumatoid arthritis and various psychiatric disorders.
From those early days, the company has been developing our offering to better meet the needs of patients. By combining the best elements of a leading-edge biotech company with the resources of a major pharmaceutical company, BMS is transforming into a new kind of enterprise: a next-generation BioPharma leader.
At the heart of this BioPharma strategy are the medicines that give meaningful hope to patients and physicians and bring value to its shareholders and customers. Since 2002, BMS introduced eight new products for the treatment of numerous serious diseases.
As well as all these products now on the market, scores of additional investigational medicines are advancing through the company’s pharmaceutical development pipeline. In fact, Bristol-Myers Squibb is recognised as having one of the most productive pipelines in the industry.
Over the years, Bristol-Myers Squibb and its employees have received awards and recognition. We have been listed as one of the best companies to work for by The Sunday Times. We have also been acknowledged as an industry leader in environment, health and safety management.
Finally, our philanthropic programmes have given new hope to some of the world’s most vulnerable citizens.
Christine (Chris) Fox, VP general manager UK and Ireland at Amgen discusses the rationale behind taking on the management of a UK affiliate in challenging times and the specificities of…
A spinout from the Roslin Institute that created Dolly the Sheep, Roslin CT is a cell and gene therapy CDMO, with a unique positioning in the field today. Its CEO,…
Jonny Ohlson, founder & CEO of Touchlight, discusses the genetic medicine revolution and the role of Touchlight in disrupting the field with its revolutionary DNA technology. You founded Touchlight Genetics…
Dr. Geoffrey Guy, chairman and founder of cannabinoid medicine pioneer, GW Pharma, outlines the potential benefits that Brexit could bring to the UK’s life sciences industry and the evolution of…
KaNDy Therapeutics, a UK-based biotech has raised £25 million to finance the Phase 2b trial of their breakthrough product in Women’s Health. Our investors and the KaNDy management team are united…
Sterling Pharma Solutions is a rapidly growing GMP contract API manufacturer based out of Dudley, Cramlington in the Northeast of England. The company was set up in its current structure…
Offering genomic sequencing and analysis, Congenica operates in the exciting world of genomic diagnosis, with a particular focus on rare diseases. Its CEO David Atkins describes the potential of Congenica’s…
Sean Richardson discusses Alexion’s focus on rare and ultra-rare diseases, the level of support for these therapies from the UK government, awareness raising, diagnostics, and his future priorities. …
With over 30 years of experience in the life sciences industry, Angela McFarlane explains why the UK will not be removed from its position in the top 3 for new…
For Ipsen, the UK is one of three global hubs, with manufacturing in Wales in which it is continuously investing, as well as large-scale R&D activities near Oxford. Ipsen’s general…
Brexit, Brexit, Brexit. It’s all anyone can talk about and yet nobody can tell you with certainty what to expect. As the UK’s impending withdrawal from the European Union looms…
Professor David Garway-Heath, a specialist in glaucoma, talks with us about the screening devices of the future, low awareness of glaucoma as a chronic disease and collaboration in training and…
See our Cookie Privacy Policy Here
